MetaVia announced that an abstract highlighting DA-1726, a novel dual OXM analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for a poster presentation at ObesityWeek® 2026, held Nov. 14-17th, in DC. bit.ly/4k6qCze #OW2026 $MTVA

MetaVia expects to report full Phase 1 Part 3A and Part 3B data for DA-1726 in Q1 2027, building on encouraging interim findings demonstrating reductions in liver fat, body weight and HbA1c.

For full DA-1726 Part 3B interim results, visit: bit.ly/3UvLSUE $MTVA

DA-1726 demonstrated statistically significant 13.5% placebo-adjusted weight loss and a reduction in mean HbA1c from 5.79% to 5.33% in participants without diabetes in Phase 1 Part 3B interim results.

Read more: bit.ly/3UvLSUE $MTVA

New Phase 1 Part 3B interim data show no new gastrointestinal adverse events reported after Week 9 through Day 109, with no gastrointestinal adverse events leading to study discontinuation.

Learn more: bit.ly/3UvLSUE $MTVA

“These are the most compelling clinical data we have generated to date supporting DA-1726’s potential as a liver-focused cardiometabolic therapy,” said Hyung Heon Kim, President and CEO of MetaVia. Read the latest data: bit.ly/3UvLSUE $MTVA

New Phase 1 Part 3B interim data demonstrate a statistically significant 68% placebo-adjusted reduction in liver fat following 16 weeks of once-weekly DA-1726 treatment.

Explore the latest findings: bit.ly/3UvLSUE $MTVA

MetaVia announced positive Phase 1 Part 3B interim data for DA-1726, demonstrating a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss after 16 weeks of once-weekly treatment.

Read more: bit.ly/3UvLSUE $MTVA

An abstract highlighting data from $MTVA's Ph. 1 clinical trial of DA-1726, a novel dual OXM analog targeting both GLP1R and GCGR receptors, has been accepted for oral presentation at the Precision Liver Symposium 2026 on Nov. 4, 2026, in Denver, CO. bit.ly/3WS9qDG

“Sarah brings an exceptional combination of clinical development leadership and regulatory expertise, particularly in advancing novel therapies for obesity, MASH and other cardiometabolic diseases,” stated Hyung Heon Kim, President and CEO. bit.ly/4jkFyJE $MTVA

MetaVia's recently appointed Chief Medical Officer, Sarah Browne, M.D., brings deep expertise in dual GLP-1/glucagon receptor agonist development, including the development of pemvidutide. Read more about her experience: bit.ly/4sblko4 $MTVA

MetaVia has appointed Sarah Browne, M.D., as Chief Medical Officer. Dr. Browne brings more than 20 years of experience in clinical development, regulatory science and medicine, with expertise in obesity, metabolic and liver diseases, including MASH. bit.ly/4jkFyJE $MTVA

GLP-1 therapies have fundamentally reshaped obesity care and opened the door to a new era of combination therapies. But what comes next?

GLP-1s have reshaped obesity care and opened the door to a new era of combination therapies. But what comes next?

In an article for @TheScientistLLC, $MTVA CMO Chris Fang, MD, explores how complementary therapies could address the broader complexity of obesity. bit.ly/4gL1wUm

What’s next for obesity treatment beyond GLP-1s?

In a new @TheScientistLLC article, MetaVia CMO Chris Fang, MD, explores how combination therapies could deliver broader metabolic benefits beyond weight loss.

MetaVia’s preclinical research with vanoglipel highlights this potential across weight loss, glucose control, and liver health.

Read the full article here: bit.ly/4gL1wUm

“We believe these findings provide important mechanistic support for the differentiated profile we continue to observe with DA-1726,” stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. Read more on the findings: bit.ly/46NAYfi $MTVA

MetaVia's DA-1726 tissue distribution study showed highest exposure in adipose (fat) tissue, with prolonged retention consistent with once-weekly dosing. These findings provide additional mechanistic support for the differentiated profile of DA-1726. bit.ly/46NAYfi $MTVA

MetaVia today announced preclinical tissue distribution results showing DA-1726-derived radioactivity is slowly absorbed and extensively distributed throughout the body after subcutaneous administration, with highest distribution seen in adipose tissue. bit.ly/46NAYfi $MTVA

MetaVia continues to advance DA-1726, with all active patients successfully reaching the highest planned dose levels of 48 mg and 64 mg in the ongoing Phase 1 Part 3 study of DA-1726, with 16-week topline data expected in the fourth quarter of 2026. bit.ly/4pZV3bd $MTVA

“During the second quarter of 2026, and subsequently, we continued to execute across both of our clinical development programs while further strengthening the differentiated profile of DA-1726 as a dual GLP-1/glucagon receptor agonist,” said H.H. Kim, CEO. bit.ly/4pZV3bd $MTVA

MetaVia today announced financial results for the second quarter ended June 30, 2026, and provided a corporate strategic update. For the full results and anticipated milestones, visit: bit.ly/4pZV3bd $MTVA

How can next-generation obesity therapies build on today's GLP-1 medicines?

In a recent interview with @LongevityTech, MetaVia CEO Hyung Heon Kim discusses DA-1726, our development strategy, and the importance of balancing efficacy with tolerability. bit.ly/4xaamjU $MTVA